Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Chadburn

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
The Annals of Thoracic Surgery|September 1, 1993
Management of lymphoproliferative disorders after cardiac transplantationJ M Chen, M L Barr, A Chadburn, et al.
Cancer|November 1, 1993
Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapyT J Garrett, A Chadburn, M L Barr, et al.
The Journal of Clinical Investigation|August 23, 2000
Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migrationS Dias, K Hattori, Z Zhu, et al.
Cancer Research|June 1, 1996
Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposisS K Boolbol, A J Dannenberg, A Chadburn, et al.
Cancer|May 20, 1998
The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevantA Chadburn, J M Chen, D T Hsu, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|January 12, 1999
Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipientsS D Zangwill, D T Hsu, M R Kichuk, et al.
Nature Medicine|November 2, 2001
Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growthD Lyden, K Hattori, S Dias, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 20, 2008
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapiesP Martin, A Chadburn, P Christos, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
The Annals of Thoracic Surgery|September 1, 1993
Management of lymphoproliferative disorders after cardiac transplantationJ M Chen, M L Barr, A Chadburn, et al.
Cancer|November 1, 1993
Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapyT J Garrett, A Chadburn, M L Barr, et al.
The Journal of Clinical Investigation|August 23, 2000
Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migrationS Dias, K Hattori, Z Zhu, et al.
Cancer Research|June 1, 1996
Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposisS K Boolbol, A J Dannenberg, A Chadburn, et al.
Cancer|May 20, 1998
The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevantA Chadburn, J M Chen, D T Hsu, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|January 12, 1999
Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipientsS D Zangwill, D T Hsu, M R Kichuk, et al.
Nature Medicine|November 2, 2001
Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growthD Lyden, K Hattori, S Dias, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 20, 2008
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapiesP Martin, A Chadburn, P Christos, et al.
Pageof 6